NCT06312423View on ClinicalTrials.gov

Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

August 30, 2024

Study Completion Date

December 30, 2024

Conditions
Immune System
Interventions
DRUG

Oligonucleotides, Phosphorothioate

Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days

Trial Locations (1)

1702

RECRUITING

CENTRO DE INVESTIGACIÓN PARA ESTUDIOS DE FARMACOLOGÍA CLÍNICA DE FASE1 EN POBLACIÓN ADULTA y DE BIOEQUIVALENCIA. Sanatorio Nuestra Señora del Pilar, Buenos Aires

Sponsors
All Listed Sponsors
collaborator

Immunalgia Therapeutics S.A.

INDUSTRY

lead

Ministry of Public Health of the Province of La Rioja

OTHER_GOV